The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 19, 2023

Filed:

Jul. 24, 2015
Applicant:

Abion Inc., Seoul, KR;

Inventors:

Young-Kee Shin, Seoul, KR;

Young-Deug Kim, Incheon, KR;

Kyoung Song, Seoul, KR;

Dong Hee Na, Daegu, KR;

Seong Hoon Jeong, Goyang-si, KR;

Dae Duk Kim, Seoul, KR;

In Soo Yoon, Muangun, KR;

Hee Jung Lee, Seoul, KR;

Sae Hyung Lee, Seongnam-si, KR;

Assignee:

Abion Inc., Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/565 (2006.01); A61K 38/21 (2006.01); A61K 47/60 (2017.01); A61K 9/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/215 (2013.01); A61K 9/0019 (2013.01); A61K 47/60 (2017.08); C07K 14/565 (2013.01); A61K 38/00 (2013.01);
Abstract

The present invention provides a PEGylated IFN-β variant and a composition for preventing or treating hyperproliferative diseases, inflammatory diseases, autoimmune diseases or viral infectious diseases, the composition comprising the PEGylated IFN-β variant as an effective ingredient. The PEGylated IFN-β variant of the present invention has an excellent anti-viral efficacy, immune regulatory function and anti-cell growth efficacy by virtue of better pharmacokinetic properties compared to native IFN-β and non-PEGylated IFN-β variants, and therefore can be used usefully against various diseases. The present invention provides good patient convenience in terms of administration due to exhibition of an excellent pharmacological activity effect upon administration and a significant increase of half-life in blood over existing interferon formulations.


Find Patent Forward Citations

Loading…